Clinical Trial Results:
            Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, para determinar si la adición de Aliskiren al tratamiento convencional, en pacientes con diabetes tipo 2 y alto riesgo de eventos cardiovasculares y renales, reduce la morbilidad y mortalidad de origen cardiovascular y renal respecto al tratamiento convencional
    
| 
                 Summary 
         | 
        |
    EudraCT number  | 
        2007-000860-25 | 
    Trial protocol  | 
        ES PT FR FI GR DE DK GB LT BE HU NL AT SE CZ IT SK | 
    Global completion date  | 
        
                                    06 Feb 2013
                             
         | 
    
| 
                 Paediatric regulatory details 
         | 
        |
    Is the trial part of an agreed EMA paediatric investigation plan?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 45 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 46 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
| 
                 Results information 
         | 
        |
    Results version number  | 
        v1(current) | 
    This version publication date  | 
        
                                    16 Apr 2016
                             
         | 
    
    First version publication date  | 
        
                                    16 Apr 2016
                             
         | 
    
    Other versions  | 
        |
    Summary report(s)  | 
                                CZOL446H2409 CT.gov results public | 
    
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.